If signed into law, H.R. 4117 would prohibit brand name pharmaceutical companies from paying generic drug companies to delay the introduction of their products to the market, an anti-competitive tactic known as "pay-for-delay."
Rep. Lloyd Doggett (TX-35) introduced H.R. 4117 on October 25, 2017. It has been referred to the Committee on Ways and Means, the Committee on the Judiciary, and the Energy and Commerce Committee.
Learn more about H.R. 4117 here.